AGGF1 Antikörper

Produktnummer ABIN7539232

Produktdetails anti-AGGF1 Antikörper

Target: AGGF1 (Angiogenic Factor with G Patch and FHA Domains 1 (AGGF1))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser AGGF1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC)

Verwendungszweck: AGGF1 antibody

Aufreinigung: Protein A purified

Immunogen: recombinant human AGGF1 (fragment)

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: WB: Use 1-5 μg/mL, IHC: 1:50

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/mL.

Buffer: PBS

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots.

Haltbarkeit: 24 months

Details zu AGGF1

Target: AGGF1 (Angiogenic Factor with G Patch and FHA Domains 1 (AGGF1))

Andere Bezeichnung: AGGF1 (AGGF1 Produkte)

Synonyme: RGD1310888 antikoerper, AGGF1 antikoerper, LOC100037685 antikoerper, im:7146636 antikoerper, zgc:152959 antikoerper, DKFZp459G1317 antikoerper, GPATC7 antikoerper, GPATCH7 antikoerper, HSU84971 antikoerper, HUS84971 antikoerper, VG5Q antikoerper, 2010009L17Rik antikoerper, 2310029P06Rik antikoerper, AW112072 antikoerper, Peg3 antikoerper, angiogenic factor with G patch and FHA domains 1 antikoerper, angiogenic factor with G-patch and FHA domains 1 antikoerper, Aggf1 antikoerper, AGGF1 antikoerper, aggf1 antikoerper, CC1G_06398 antikoerper

Hintergrund: Angiogenic factor VG5Q, hVG5Q, G patch domain-containing protein 7, Vasculogenesis gene on 5q protein,AGGF1, also known as VG5Q, was identified by its association with Klippel Trenaunay syndrome (KTS), a congenital vascular morphogenesis disorder (1 3). AGGF1 is expressed by vascular endothelial cells in many tissues (1). It appears to be secreted and promotes endothelial cell proliferation following interactions with endothelial cell surfaces (1). AGGF1 also directly interacts with TWEAK (1), a TNF superfamily ligand with angiogenic properties (8). It was shown that AGGF1 is involved in establishing venous identity in zebrafish embryos. Overexpression of AGGF1 led to increased angiogenesis and increased lumen diameter of veins, whereas knockdown of AGGF1 expression resulted in defective vasculogenesis and angiogenesis. Overexpression of AGGF1 increased expression of venous markers (e.g. VEGFR-3/FLT4), but had little effect on arterial markers (e.g. Notch5). Knockdown of AGGF1 expression resulted in a loss of venous identity (loss of expression of VEGFR-3/FLT4, Ephb4 and Dab2), but had no effect on the expression of arterial development. It was further shown that AGGF1 activates AKT, and that decreased AGGF1 expression inhibits AKT activation. Overexpression of constitutively active AKT rescues the loss of venous identity caused by AGGF1 downregulation. These results indicate that AGGF might be an angiogenic factor with an important role in the specification of vein identity and suggests that AGGF1-mediated AKT signaling is responsible for establishing venous cell fate.

Gen-ID: 55109

UniProt: Q8N302